OKYO Pharma Limited (OKYO)
| Market Cap | 87.64M +3.1% |
| Revenue (ttm) | n/a |
| Net Income | -8.95M |
| EPS | -0.24 |
| Shares Out | 52.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 135,390 |
| Open | 1.599 |
| Previous Close | 1.550 |
| Day's Range | 1.480 - 1.670 |
| 52-Week Range | 1.340 - 3.200 |
| Beta | 0.02 |
| Analysts | Strong Buy |
| Price Target | 8.33 (+398.8%) |
| Earnings Date | Jul 20, 2026 |
About OKYO
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for OKYO stock is "Strong Buy." The 12-month stock price target is $8.33, which is an increase of 398.80% from the latest price.
News
Okyo Pharma management to meet virtually with Piper Sandler
Virtual Meeting to be held on August 25-26 hosted by Piper Sandler.
Okyo Pharma CSO Raj Patil purchases 3,363 shares at $1.49
Okyo Pharma (OKYO) announced that Raj Patil, chief scientific officer of Okyo Pharma has increased his holdings with the purchase of 3,363 of the company’s ordinary shares on Nasdaq at…
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
Okyo Pharma director John Brancaccio acquires 5,000 shares at $1.38
OKYO Pharma (OKYO)announced that OKYO Pharma’s Non-Executive Director, John Brancaccio has purchased 5,000 of the Company’s ordinary shares on NASDAQ at $1.48 per share, bringing his total holding to ...
OKYO Pharma Announces Purchase of Shares by Director
LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
Okyo Pharma CEO Robert Dempsey purchases 15,000 shares at $1.54
Okyo Pharma (OKYO) announced that Okyo Pharma’s CEO, Robert Dempsey, has purchased 15,000 of the company’s ordinary shares on Nasdaq at $1.54 per share.
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer
LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
Okyo Pharma says Chairman Gabriele Cerrone buys 22,500 shares at $1.45/share
OKYO Pharma (OKYO) announced that its Chairman, Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of…
OKYO Pharma Announces Purchase of Shares by Chairman
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
Okyo Pharma says CDO Gary Jacob purchases 3,500 shares for $1.40 per share
OKYO Pharma (OKYO) Limited announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase of 3,500 of the company’s…
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
Okyo Pharma CMO Flavio Mantelli purchases 20,000 shares at $1.40
Okyo Pharma (OKYO) announced that Okyo Pharma’s CMO, Flavio Mantelli, has purchased 20,000 of the company’s ordinary shares on Nasdaq at $1.40 per share.
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
Okyo Pharma chairman Gabriele Cerrone buys 25,000 shares at $1.40 per share
Okyo Pharma (OKYO) announced that its chairman, Gabriele Cerrone, through Panetta Partners, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 25,000…
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
LONDON and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
OKYO Pharma Annual report: Q4 2026
OKYO Pharma has published its Q4 2026 annual report on July 20, 2026.
OKYO Pharma Slides: Investor presentation
OKYO Pharma has posted slides in relation to its latest quarterly earnings report, which was published on July 13, 2026.
Okyo Pharma price target lowered to $5 from $7 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Okyo Pharma (OKYO) to $5 from $7 and keeps a Buy rating on the shares. The firm cites the company’s increased share…
Okyo Pharma receives feedback from FDA Type D meeting on urcosimod pathway
Okyo Pharma (OKYO) announced feedback from its FDA Type D meeting, validating the company’s regulatory and clinical path forward for urcosimod and supporting advancement into a global Phase 3 pivotal…
OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain
LONDON and NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat...
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative disease OKYO's introduction to the broader ophthalmology community at ASCRS ...
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
LONDON and NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa...